Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.

American journal of hematology·2026
Same author

Treatment strategies in giant cell arteritis and polymyalgia rheumatica: beyond glucocorticoids.

Nature reviews. Rheumatology·2026
Same author

Giant Cell Arteritis.

Annals of internal medicine·2026
Same author

Significance of positive rheumatoid factor in ANCA-associated vasculitis.

Clinical and experimental rheumatology·2026
Same author

Structured Vascular Segment Analysis for Giant Cell Arteritis: A Proposed Scoring System for CT Angiography-Based Diagnosis.

AJNR. American journal of neuroradiology·2026
Same author

A Delphi exercise informing the development of criteria to measure response to treatment in giant cell arteritis.

Seminars in arthritis and rheumatism·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

ポリミアルギア・レウマチア

Tanaz A Kermani1, Kenneth J Warrington

  • 1Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Lancet (London, England)
|October 12, 2012
PubMed
まとめ
この要約は機械生成です。

ポリミアルギー・レウマチア (Polymyalgia rheumatica) は,高齢者の痛みや硬さを引き起こす炎症性疾患である. 診断は臨床的評価に依存し,グルココルチコイドが役立つ一方で,再発や副作用は一般的であり,より良い治療が必要になります.

関連する実験動画

科学分野:

  • レウマトロジーの病理学
  • 免疫学 免疫学とは
  • 内科内科は,内科の内科である.

背景:

  • ポリミアルギー・レウマチア (PMR) は,50歳以上の個人に影響する慢性炎症性疾患です.
  • 首,肩,股関節,大腿の痛みと朝の硬直が特徴です.
  • 診断は臨床的であり,特定の検査は行われないが,炎症マーカーが上昇する可能性がある.

研究 の 目的:

  • ポリミアルギア・レウマチカの重要な側面を要約します.
  • 診断上の課題と現在の治療アプローチを強調する.
  • 病原性の理解を深める必要性を強調する.

主な方法:

  • 臨床評価と暫定的な分類基準 (2012 EULAR/ACR).
  • 周関節炎を示すイメージング研究 (超音波検査,MRI) のレビュー.
  • 患者のサブセットで大動脈血管病変 (巨大細胞動脈炎) と関連がある.

主要な成果:

  • PMRの症状は,しばしば,脊椎関節炎やリウマチ性関節炎のような他の炎症性関節疾患を模倣する.
  • 画像検査では,主に関節周炎症の過程が示されています.
  • グルココルチコイド治療は症状の緩和をもたらすが,頻繁な再発と著しい罹病率に関連している.

結論:

  • ポリミアルジア・レウマティック症の診断は,臨床的根拠を持ち続け,他の炎症性疾患と区分することは困難です.
  • 現在の標準的なグルココルチコイド治療は,症状管理に有効ですが,限界があります.
  • PMRの病原性に関するさらなる研究は,よりターゲットを絞った免疫療法の開発に不可欠です.